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Introduction
Systemic lupus erythematosus (SLE) is a devastating, multifacto-
rial autoimmune disease caused by a panoply of immunoregula-
tory, genetic, environmental, hormonal, and epigenetic com-
ponents. The pathogenesis of SLE includes both the innate and 
adaptive branches of the immune response (1, 2), involving both B 
and T lymphocytes and affecting the function of monocytes, mac-
rophages, dendritic cells, and other cellular and humoral com-
ponents (3). T cells, which infiltrate vital organs and tissues, e.g., 
blood, spleen, kidney, lung, and brain, often produce proinflam-
matory cytokines that ultimately cause organ damage (1, 4). Dou-
ble negative T cells (DN T cells, CD3+CD8–CD4–TCRαβ+) infiltrate 
the kidney of SLE patients and lupus-prone MRL/MpJ-fas lpr 
(MRL/lpr) mice and are major contributors to the lymphadenopa-
thy and splenomegaly phenotypes in lupus (5). In addition, autore-
active B cells in SLE function to produce autoantibodies, causing 
accumulation of immune complexes and induction of inflamma-
tory responses in tissues (6).
Aberrant expression of immunoregulatory signaling proteins 
contributes to tissue injury and clinical manifestation of SLE. For 
example, kinases, such as calcium/calmodulin-dependent protein 
kinase IV (CaMK4), are increased in SLE T cells and are involved 
in the transcriptional regulation of genes that lead to the impair-
ment of cytokine production (7), Similarly, abnormalities in genes 
encoding protein phosphatases are also causally involved in auto-
immunity. For example, protein phosphatase 2A (PP2A) is induced 
in both expression and activity in T cells, promoting inflammation 
through aberrant cytokine production and tissue infiltration (8). 
The C1858T allele of protein tyrosine phosphatase, non-receptor 
type 22 (PTPN22) confers increased risk for SLE, rheumatoid 
arthritis (RA), and type 1 diabetes, likely through dysregulation of 
its binding to the C-terminal Src tyrosine kinase (Csk), and thereby 
leads to aberrant regulation of T cell activation (9–12). In addition, 
a mutation in CD45, 77C/G, is linked to the onset of autoimmune 
hepatitis (13). More recently, an SLE susceptibility locus on chro-
mosome 12 (12q24) was identified in the same region as the SH2 
domain–containing PTP (SHP2) (14), suggesting that it too may be 
involved in the pathology and/or progression of SLE, although this 
has not yet been determined.
SHP2 is a nonreceptor PTP containing 2 SH2 domains, a 
catalytic PTP domain and a C-terminal tail with 2 tyrosine phos-
phorylation sites and a proline-rich motif (15–17). While normal-
ly inactive in the basal state, binding of a phosphotyrosyl (pY) 
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tis and glomerulonephritis phenotype (38). We performed an 
immune-complex phosphatase assay in spleen lysates generated 
from 18-week-old WT, MRL/MpJ, and MLR/lpr female mice and 
found that SHP2 activity, as in human lupus PBMCs, was signifi-
cantly increased (~5-fold higher) in MLR/lpr mice, as compared 
with both WT and MRL/MpJ controls (Figure 1B).
To determine whether SHP2 activity affects lupus pathogenic-
ity, we utilized a hydroxyindole carboxylic acid–based SHP2 inhibi-
tor (11a-1) that anchors to the SHP2 active site, with strong potency 
(IC50 200 nM) and selectivity (>5-fold against any of 20 other 
PTPs) (39). We treated WT, MRL/MpJ, and MRL/lpr female mice 
with either vehicle or 11a-1 (7.5 mg/kg/d) for a period of 6 weeks, 
beginning at 12 weeks, the age of SLE disease onset in MRL/lpr 
mice. Immune complexes derived from spleens isolated from SHP2 
inhibitor–treated MRL/lpr mice showed normalized SHP2 activity, 
with no effects of the inhibitor in WT or MRL/MpJ lysates (Figure 
1B). Importantly, the inhibitor was specific to SHP2, as activity of 
PTPN22, another tyrosine phosphatase upregulated and involved in 
SLE pathogenesis, or SHP1, a closely related SHP family member, 
was not affected by treatment with the SHP2 inhibitor (Supplemen-
tal Figure 1, A and B; supplemental material available online with 
this article; doi:10.1172/JCI87037DS1). Moreover, 11a-1 treatment 
was potent and reversible, as SHP2 activity returned to the same 
level as that of vehicle-treated lysates following serial washes of the 
SHP2 immune-complex (Supplemental Figure 1C).
SHP2 modulates ERK/MAPK, but not AKT/mTOR, signaling in 
SLE. PI3K/AKT/mTOR signaling is an important pathway regu-
lated by SHP2 (40) whose activation promotes survival as well 
as cytokine/inflammatory signaling in SLE (41). Here, and con-
sistent with inflammatory responses that can activate this path-
way, MRL/lpr spleen lysates showed increased phosphorylation 
of both AKT and p70s6K, the downstream effector of mTOR, in 
18-week-old MRL/lpr female mice (Figure 1C). However, 11a-1 
drug treatment did not normalize the aberrant AKT or p70S6K 
activities (Figure 1C), suggesting SHP2 plays a modest role, if any, 
in this signaling pathway in SLE disease.
SHP2 is also a key positive regulator of ERK/MAPK signal-
ing by nearly all receptor tyrosine kinase, cytokine, and integrin 
receptors (15–17, 42). Aberrant regulation of this pathway there-
fore could contribute to immune dysfunction in lupus through 
epigenetic effects on gene expression (43, 44). Indeed, decreased 
ERK/MAPK signaling in T cells is associated with abnormal epi-
genetic modification and overactivation of T cells (45). To assess 
the effects of increased SHP2 activity on ERK signaling in SLE, we 
measured ERK1/2 phosphorylation in spleen lysates isolated from 
18-week-old WT, MRL/MpJ, and MLR/lpr female mice. Despite 
elevated SHP2 phosphatase activity, which normally induces ERK 
phosphorylation, we found that ERK/MAPK activity was signifi-
cantly decreased in MRL/lpr lysates, as compared with WT and 
MRL/MpJ controls (Figure 1D); indeed, this result is consistent 
with previous observations of ERK/MAPK activity in SLE-prone 
mice (46). Importantly, 11a-1 reversed the aberrant ERK/MAPK 
signaling in MRL/lpr splenocytes (Figure 1D), suggesting signal-
ing specificity of SHP2 for this pathway in SLE.
Normalization of SHP2 activity ameliorates skin lesions, increases 
life span, and reduces lupus-associated organ damage in lupus-prone 
MRL/lpr mice. To delineate the contribution of SHP2 activity on 
protein to SHP2 alters its conformation, unfolding the enzyme 
and activating the phosphatase to elicit downstream signaling 
(18–20). Missense SHP2 mutations are found in approximately 
50% of cases of Noonan syndrome (NS), a common (~1:1000–
1:2500) autosomal dominant disorder characterized by mul-
tiple, variably penetrant defects (21, 22). Nearly all NS muta-
tions of SHP2 are catalytically hyperactivated, i.e., they have 
increased PTP activity (23, 24) and behave as gain-of-function 
(GOF) alleles (23–29). Importantly, to date, over 50 cases of NS 
have been linked to the development of SLE, as demonstrated 
by the onset of polyarthritis, pericarditis, and production of 
antinuclear and anti-DNA antibodies in these patients (30–35). 
Taken together, these data suggest that a functional and/or 
genetic association between SLE and SHP2 activity likely exists.
Despite numerous efforts to understand the cellular and 
mechanistic complexities of SLE, no unifying hypothesis exists 
to explain the role of altered signal transduction networks in the 
pathogenesis of this disease. Here, for what we believe is the first 
time, we provide evidence that SHP2 activity is increased in both 
lupus-prone mice and in human SLE patients. Further, its inhibi-
tion increases life span, suppresses crescentic glomerulonephritis, 
reduces spleen size, and diminishes skin lesions in MRL/lpr mice. 
Treated mice also have reduced numbers of DN T cells, normal-
ized ERK/MAPK signaling, and decreased production of IFN-γ 
and IL-17A/F, critical cytokines involved in SLE-associated organ 
damage and also found to be increased in human SLE patient 
serum. Moreover, the SHP2 inhibitor reduces the proliferation 
of cultured human lupus T cells and decreases the production of 
IFN-γ and IL-17A/F in vitro, further implicating SHP2 in human 
lupus-associated immunopathology. Taken together, we identify 
SHP2 as a critical regulator of SLE disease and suggest targeting of 
its activity as a potent therapy for lupus patients.
Results
SHP2 activity is increased in human SLE patients and in lupus-prone 
MRL/lpr mice. To assess whether SHP2 has any functional conse-
quence in SLE pathogenesis, we performed an immune-complex 
phosphatase assay to measure SHP2 activity in human peripheral 
blood mononuclear cells (PBMCs) isolated from normal female 
donors or SLE disease-active female patients. SHP2 activity was 
significantly increased (~4-fold) in lupus PBMCs, as compared 
with normal cells, suggesting SHP2 activity is altered in human 
SLE disease (Figure 1A). We next utilized lupus-prone MRL/lpr 
mice, a murine model that recapitulates human disease and in 
which SLE susceptibility correlates with mutations at several loci 
(36, 37). These mice also contain an autosomal recessive lpr (lym-
phoproliferation) gene mutation, which is thought to be causal to 
the early onset (12 weeks of age) of the disease, which includes 
severe lymphadenopathy, autoantibody production, circulating 
immune complexes, glomerulonephritis, splenomegaly, arthritic 
changes, pulmonary lesions, progressive histopathologic chang-
es, including lymphocytic and monocytic cell infiltrations, and 
destruction of normal tissue architecture, and which culminates 
in death by approximately 24 weeks of age (38). For experimental 
controls, we used female C57BL/6 WT mice as well as the lupus 
background strain MRL/MpJ mice, which do not have the reces-
sive lpr gene mutation, but develop a milder and later-onset arthri-
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of glomerulonephritis, proteinuria, 
and eventually, renal failure (41). To 
determine whether SHP2 activity is 
involved in SLE-mediated kidney 
dysfunction, we analyzed kidneys 
from 18-week-old WT, MRL/MpJ, 
and MRL/lpr female mice treated for 
6 weeks with either vehicle or 11a-1. 
We observed that the MRL/lpr mice 
treated with SHP2 inhibitor had a nor-
malized appearance (Figure 2E), reduced kidney weight (Figure 
2F), and a significant reduction in proteinuria (Figure 2G), sug-
gesting overall improved kidney function. Histologically, kid-
neys from MRL/lpr mice developed progressive crescentic glo-
merulonephritis, massive immune cell infiltration, and induced 
fibrosis (Figure 2H and Supplemental Figure 2, A and B), as com-
pared with WT and MRL/MpJ controls. In contrast, treatment of 
MRL/lpr mice with the SHP2 inhibitor prevented the progression 
of kidney disease in SLE-prone mice (Figure 2H and Supple-
mental Figure 2), suggesting that normalization of SHP2 activity 
ameliorates SLE-associated kidney damage.
Furthermore, treatment of the mice with the SHP2 inhibitor did 
not evoke unwarranted effects, as there was no weight loss or any 
other obvious adverse effect observed as a consequence of 11a-1 
treatment (Figure 2I). Finally, Kaplan-Meier survival curves for 
MRL/lpr mice treated with 11a-1 (7.5 mg/kg/d) from 12 weeks to 
an SLE phenotype, we treated WT, MRL/MpJ, and MRL/lpr mice 
with either vehicle or 11a-1 for a period of 6 weeks, beginning at 
12 weeks of age. MRL/lpr 11a-1–treated mice showed dramatically 
reduced skin lesions and had an overall healthier appearance, as 
compared with WT, MRL/MpJ, or vehicle-treated MRL/lpr mice 
(Figure 2A). Moreover, in response to the SHP2 inhibitor, spleens 
isolated from MRL/lpr mice were substantially decreased (Fig-
ure 2B), with lower spleen weights (Figure 2C) and reduced total 
number of splenocytes (Figure 2D) as compared with MRL/lpr 
vehicle-treated spleens. No effects of the inhibitor were observed 
in spleens from WT or MRL/MpJ controls (Figure 2, B–D).
In addition to spleen, the kidney is also severely affected 
in SLE; as disease progresses, the kidney rapidly deteriorates, 
increasing mesangial cell proliferation, inducing vascular col-
lapse, and enhancing T cell and immune complex accumula-
tion (47). Together, this deterioration culminates in the onset 
Figure 1. SHP2 activity is upregulated 
in both lupus patients and lupus-prone 
MRL/lpr mice, the normalization of which 
reverses aberrant ERK/MAPK signaling. 
(A) SHP2 immune complex PTP assays 
were conducted using pNPP as a substrate 
on human PBMC lysates and (B) mouse 
splenic lysates generated from 18-week-
old control C57BL/6 WT, strain-control 
MRL/MpJ (MpJ), and lupus-prone MRL/lpr 
(lpr) female mice that were either vehicle 
or SHP2 inhibitor (11a-1) treated (7.5 mg/
kg/d) for 6 weeks, starting at 12 weeks of 
age. Immunoblotting controls for levels 
of immunoprecipitated SHP2, showing 
comparable recovery, are shown below each 
figure. n = 6 human samples/group and 
n = 3–8 mice/group, respectively. Splenic 
lysates isolated from 18-week-old WT, 
MpJ, and MRL/lpr mice subjected to either 
vehicle or 11a-1 were immunoblotted with 
(C) anti–phospho-AKT and anti–phospho-
p70S6K or (D) anti–phospho-ERK, as indi-
cated, followed by anti-AKT, anti-p70S6K, 
and anti-ERK, respectively, to control for 
loading. Parallel experimental samples 
were blotted with anti-SHP2 or anti-
GAPDH to determine expression levels of 
these proteins. Quantification of data (n = 
3 mice/group) is shown to the right of each 
representative Western blot figure. Data 
represent mean ± SEM; *P < 0.05, 1-way or 
2-way ANOVA with Holm-Sidak post-test 
when ANOVA was significant.
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D and E) in 11a-1–treated MRL/lpr spleens, as compared with WT, 
MRL/MpJ, and vehicle-treated controls, suggesting an inhibition 
of overall T cell–associated pathogenesis in these mice in the pres-
ence of the SHP2 inhibitor. Interestingly, no effects of SHP2 were 
observed on regulatory T (CD4+CD25+) cells (Figure 4E and Sup-
plemental Figure 4), suggesting that the decrease in CD4+, CD8+, 
and DN T cells is not mediated by indirect effects of the inhibitor 
on regulatory T cells, but rather by inhibition of SHP2 directly on 
CD4+, CD8+, and DN T cell subsets.
To confirm whether these effects are a direct consequence 
of SHP2’s involvement in T cell proliferation, we isolated and 
cultured T cells from splenocytes for 48 hours in the presence of 
either vehicle or 11a-1 and either in the absence or presence of anti-
bodies directed against CD3 and CD28 (anti-CD3 and -CD28). 
Proliferation of both naive and activated T cells was significantly 
inhibited in the MRL/lpr 11a-1–treated cells, whereas no effects of 
the inhibitor were observed in WT or MRL/MpJ control cells, both 
in the presence and absence of activating antibodies (Figure 4F). 
Importantly, SHP2 was necessary for proliferation specifically, as 
no effects on viability were observed in either MRL/lpr vehicle- 
or inhibitor-treated splenocyte T cells, either in the presence or 
absence of activating antibodies (Figure 4G).
To further assess the SHP2-dependent cellular immune 
responses in tissues, we used flow cytometry to measure T cell, 
macrophage, and neutrophil infiltration in kidneys of vehicle- and 
inhibitor-treated MRL/lpr female mice. As in immune cell subsets 
isolated from spleen (Figure 4), the SHP2 inhibitor reduced the 
overall number of leukocytes (CD45+ cells) (Supplemental Fig-
ure 5A), specifically targeting infiltration of T cells (CD45+CD3+) 
(Supplemental Figure 5B) and reducing the overall number of all 
CD4+, CD8+, and DN T cells (Supplemental Figure 5C). In addi-
tion, we observed a significant reduction in infiltrating macro-
phages (CD45+CD3–CD11b+Ly6G–) and neutrophils (CD45+CD3–
CD11b+Ly6G+) in inhibitor-treated SLE kidneys (Supplemental 
Figure 5D). Taken together, these data suggest that 11a-1 treat-
ment may prevent the migration of T cells and inflammatory cells 
into SLE-targeted organs such as the spleen and kidney.
SHP2 signaling modulates DN T cell proliferation in SLE. We pre-
viously found that only DN T cells were affected by the SHP2 inhibi-
tor in whole blood, suggesting that this cell subtype is more sensitive 
to SHP2 regulation in SLE (Figure 3D). Moreover, while autoreactive 
DN T cells are not typical in a normal individual’s circulation, they 
can be produced by CD8+ T cells in SLE patients (48, 49) and are 
likely implicated in the pathogenesis of both SLE patients (50) and 
MRL/lpr mice (5). Therefore, to examine the mechanism of regu-
lation of SHP2 specifically in these cells, we isolated and cultured 
DN T cells from the lymph nodes of 18-week-old MRL/lpr female 
26 weeks of age showed a remarkable improvement in survival rate 
of lupus-prone animals; more than 80% of 11a-1–treated mice sur-
vived at a time point in which all vehicle-treated MRL/lpr mice had 
died (Figure 2J). Together, these data indicate that SHP2 activity 
is a positive mediator of SLE and that normalization of its activity 
prolongs life and ameliorates lupus pathogenicity in MRL/lpr mice.
SHP2 modulates the immune response in SLE. To measure the 
contribution of SHP2 activity on the immune response in SLE, 
we isolated whole blood immune cell subsets from vehicle- or 
11a-1–treated WT, MRL/MpJ, and MRL/lpr female mice. We found 
that the inhibitor reduced the elevated wbc count in the MRL/lpr 
mice (Figure 3A). No elevation or effects of 11a-1 treatment were 
observed in wbc isolated from WT or MRL/MpJ mice (Figure 3A). 
Moreover, no differences in rbc or platelet counts were observed 
in any these groups (Supplemental Figure 3A) with or without 
11a-1 treatment, suggesting SLE does not play a significant role in 
altering these populations in these mice. Of the wbc population, 
only lymphocytes, but not neutrophils, monocytes, eosinophils, 
or basophils, were significantly decreased by 11a-1, even though 
the overall total numbers of neutrophils, monocytes, and eosino-
phils were each significantly elevated in MRL/lpr mice (Figure 
3B and Supplemental Figure 3B). Furthermore, despite having no 
effect on the total percentage of circulating B cells (CD45+CD19+) 
(Figure 3C and Supplemental Figure 3C), 11a-1 treatment reduced 
the total percentage of T cell lymphocytes (CD45+ TCRαβ+) in 
MRL/lpr mice (Figure 3C and Supplemental Figure 3C). Indeed, 
of the circulating T cell subpopulations, SHP2 inhibition more 
selectively targeted DN T cells (CD45+ CD4–CD8–TCRαβ+), with 
minimal effects observed in CD4+ (CD45+ CD4+CD8–TCRαβ+) or 
CD8+ (CD45+ CD4–CD8+TCRαβ+) T cells in MRL/lpr mice (Figure 
3D and Supplemental Figure 3C), suggesting a positive role for 
SHP2 in modulating DN T cells specifically.
Decreasing SHP2 activity blocks abnormal T cell proliferation. To 
determine the mechanism by which SHP2 potentiates the abnor-
mal immune response in SLE, we analyzed immune cell subsets 
in spleens isolated from 18-week-old vehicle- or 11a-1–treated 
WT, MRL/MpJ, or MRL/lpr female mice. Concomitant with 
the decrease in total splenocytes (Figure 2, B–D), we found that 
11a-1 treatment significantly reduced the total number of T 
(CD3+) cells (Figure 4, A and B), but not of B (CD19+) cells (Fig-
ure 4, A and C) isolated from MRL/lpr spleens. Indeed, and in 
contrast, 11a-1 increased the total number of B cells in MRL/lpr 
spleens (Figure 4C), suggesting that inhibition of SHP2 may 
trigger a feedback mechanism to promote proliferation and/or 
expansion of these cells.
Next, we investigated the effects of SHP2 on T cell subsets and 
found reduced numbers of CD4+, CD8+, and DN T cells (Figure 4, 
Figure 2. Inhibition of SHP2 activity reduces skin lesions, decreases splenomegaly, normalizes kidney structure and function, and prolongs MRL/lpr 
longevity. Representative photographs of (A) skin lesions or (B) spleens from WT, MpJ, and MRL/lpr mice treated with vehicle or 11a-1 for 6 weeks. (C) Spleen 
weight to tibia length ratios (n = 8 mice/group) and (D) total splenocyte counts (n = 3–5 mice/group) from 18-week-old WT, MpJ, and MRL/lpr female mice 
treated for 6 weeks with either vehicle or 11a-1 (7.5 mg/kg/d). (E) Representative photograph of kidneys, (F) histograms showing kidney weight to tibia 
length (n = 8 mice/group), and (G) ratio of albumin to creatinine in urine (n = 7–8 mice per group), and (H) representative H&E-stained kidney sections and 
pathological scores (n = 4 mice/group) from 18-week-old WT, MpJ, and MRL/lpr female mice treated for 6 weeks with vehicle or 11a-1 (7.5 mg/kg/d). Scale 
bar: 500 μm. (I) Body weight measurements for 12- to 18-week-old WT, MpJ, and MRL/lpr mice subjected to either vehicle or 11a-1 (n = 8 mice/group). (J) 
Kaplan-Meier survival curve in 12- to 26-week-old WT, MpJ, and MRL/lpr mice subjected to either vehicle or 11a-1. n = 5 mice/group. Note: all vehicle-treated 
MRL/lpr mice died by 26 weeks, whereas only 20% of the 11a-1–treated mice died at that same time point. *P < 0.01; #P < 0.05, where P values were derived 
from 2-way ANOVA with Holm-Sidak post-test when ANOVA was significant.
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mice. Cells were activated with anti-CD3 and anti-CD28 antibod-
ies and were then cultured with either vehicle or 11a-1 for 48 hours. 
While the use of the SHP2 inhibitor had no significant effects on 
AKT or pS6RP activities in MRL/lpr DN T cells (Figure 5A), ERK/
MAPK activation was increased (Figure 5B), consistent with effects 
observed in spleen lysates ex vivo (Figure 1). Moreover, proliferation 
of MRL/lpr DN T cells was reduced by inhibitor treatment, both 
at baseline and in response to antibody activation, as compared 
with vehicle-treated MRL/lpr cells (Figure 5C). Importantly, this 
decrease in the total number of DN T cells was not a consequence 
of reduced viability, as this remained unaffected between vehicle- 
and inhibitor-treated groups, both in the presence and absence of 
CD3 and CD28 antibodies (Figure 5D) and consistent with effects 
observed in splenocytes (Figure 4, F and G). Together, these 
data suggest that a mechanism of regulation by SHP2 in SLE is to 
promote DN T cell proliferation.
SHP2 activity induces production of a specific subset of cyto-
kines in SLE. Aberrant regulation of cytokines, such as IL-6, IL-
17A/A homodimer, type II IFN-γ, and TNF-α, is closely linked to 
pathogenesis of SLE, playing key roles in the regulation of sys-
temic inflammation, local tissue damage, and immunomodula-
tion (51–62). To determine whether SHP2 activity is involved in 
modulating cytokine production in SLE, we collected serum from 
either vehicle- or inhibitor-treated WT, MRL/MpJ, and MRL/lpr 
mice and measured circulating concentrations of IFN-γ, TNF-α, 
IL-17A/A, IL-17A/F, and IL-6. Despite significant upregulation of 
multiple cytokines in MRL/lpr mice, as compared with WT and 
MRL/MpJ mice (Supplemental Figure 6), treatment of the SLE-
prone mice with 11a-1 only reduced the production of IL-17A/F 
heterodimer (Figure 6A) and IFN-γ (Figure 6B). No significant dif-
ferences in TNF-α, IL-17A/A homodimer, or IL-6 were observed 
between vehicle- and inhibitor-treated SLE-derived serum sam-
ples (Supplemental Figure 6). Further, this result was validated in 
DN T cells isolated from MRL/lpr lymph nodes and cultured for 
120 hours in the presence of activating antibodies CD3 and CD28. 
Here, we found that activated cells had signifi-
cantly increased levels of IL-17A/F (Figure 6C) 
and IFN-γ (Figure 6D), as compared with nonac-
tivated controls. These cytokines were also sig-
nificantly reduced following treatment with 11a-1 
(Figure 6, C and D), suggesting a functional role 
for SHP2 in mediating the production of IFN-γ 
and IL-17A/F by DN T cells in SLE. To further val-
idate these findings, we found that the degree of kidney dysfunc-
tion in MRL/lpr mice directly correlated with induced serological 
levels of both IL-17A/F (Figure 6E) and IFN-γ (Figure 6F), validat-
ing the pathogenic properties of these cytokines in SLE.
SHP2 activity is not involved in autoantibody production. In its 
early stages, SLE is characterized by generalized B cell activation, 
autoreactive B cell expansion, and hypergammaglobulinemia, all of 
which induce DNA-specific autoantibody production (41). To deter-
mine whether SHP2, in addition to T cell function, is involved in B 
cell regulation of SLE, we measured levels of autoantibody produc-
tion in serum derived from vehicle- or 11a-1–treated WT, MRL/MpJ, 
and MRL/lpr female mice. Levels of anti-dsDNA and total IgG anti-
bodies were not reduced in response to SHP2 inhibitor treatment 
in MRL/lpr mice (Figure 7, A and B) despite the increase in total B 
cell numbers in MRL/lpr splenocytes (Figure 4C), suggesting SHP2 
does not affect B cell function in SLE. This finding was further vali-
dated by measuring the numbers of MRL/lpr spleen extrafollicular 
T helper cells (TCRβ+CD4+PSGL1–CD62L–) (Figure 7C), plasma-
blasts (TCRβ–CD44hiB220+CD138+) (Figure 7D), and plasma cells 
(TCRβ–CD44hiB220–CD138+) (Figure 7D), which are each induced 
to help mediate production of autoantibodies. Here, both vehicle- 
and 11a-1–treated MRL/lpr spleens showed similar cell numbers of 
these populations, confirming that B cell function is unaffected and 
independent of SHP2 activity in SLE (Figure 7, C and D).
SHP2 activity is involved in human SLE, inducing T cell pro-
liferation and increasing production of IFN-γ and IL-17 A/F. To 
determine the clinical relevance of our findings, we measured 
serological levels of IL-17A/F and IFN-γ from disease-active 
SLE patients. We found that both IL-17A/F (Figure 8A) and 
IFN-γ (Figure 8B) were significantly increased in SLE patients. 
Next, we cultured T cells isolated from human SLE patient 
PBMCs, either in the presence or absence of anti-CD3 and 
anti-CD28 antibodies, for 48 hours. T cells derived from lupus 
patients had increased clonal expansion (Figure 8C) and signifi-
cantly increased proliferation after only 48 hours in culture (Fig-
Figure 3. Inhibition of SHP2 reduces the number of 
circulating DN T cells in peripheral blood of MRL/lpr 
mice. Total number of circulating (A) wbc and (B) 
lymphocytes in peripheral blood of 18-week-old WT, 
MpJ, and MRL/lpr female mice treated for 6 weeks 
with vehicle or 11a-1 (7.5 mg/kg/d). n = 7 mice/group. 
Peripheral blood from 18-week-old MRL/lpr female mice 
treated with vehicle or 11a-1 for 6 weeks was collected to 
determine percentage of (C) B and T cells and (D) various 
T cell subsets, including CD3+CD4+CD8–TCRαβ+ (CD4+), 
CD3+CD4–CD8+TCRαβ+ (CD8+), and CD3+CD4–CD8–TCRαβ+ 
(DN) T cells in CD45+ leukocytes. n = 4 mice/group. *P 
< 0.05, 2-way ANOVA with Holm-Sidak post-test when 
ANOVA was significant.
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Figure 4. Normalization of SHP2 activity reduces T cell proliferation in MRL/lpr spleens. (A) Representative flow cytometry of T cells (CD3+) and B cells 
(CD19+) isolated from spleens of 18-week-old WT, MpJ, and MRL/lpr female mice treated for 6 weeks with vehicle or 11a-1 (7.5 mg/kg/d). Quantification 
of the total number of (B) T cells and (C) B cells isolated from MRL/lpr spleens. n = 3–5 mice/group. (D) Representative flow cytometry of CD3+ gated T 
cells to identify T cell subsets: CD4+, CD8+, and CD4–CD8– cells in spleens from 18-week-old WT, MpJ, and MRL/lpr female treated with vehicle or 11a-1 for 6 
weeks. (E) Quantification of T cell subsets in WT, MpJ, and MRL/lpr mouse spleens. n = 3–5 mice/group. T cells isolated from spleens of 18-week-old WT, 
MpJ, and MRL/lpr mice were cultured (1 × 105 cells/well) in 96-well plates for 48 hours in the presence of vehicle (DMSO) or 11a-1 (10 μg/ml) and either in the 
presence or absence of T cell–activating antibodies CD3 and CD28 to determine (F) proliferation (change in total number of cells) and (G) viability (measure 
of cell death). n = 3 independent experiments. *P < 0.01; #P < 0.05, 2-way ANOVA with Holm-Sidak post-test when ANOVA was significant.
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these cytokines was significantly reduced following treatment with 
11a-1 (Figure 8, F and G), further suggesting that the pathogenesis of 
SLE may directly be correlated to the expression of these cytokines.
Discussion
There is no cure for lupus, a disease that can be fatal. Moreover, 
development of novel, disease-specific, and side effect–free drugs 
for SLE have met unprecedented obstacles (63). Here, our data are 
the first, to our knowledge, to suggest that increased SHP2 activ-
ity and the aberrant effects this has on disease-active T cell pro-
liferation and downstream cytokine production are integral to the 
molecular and pathophysiological effects of SLE. Furthermore, 
use of a potent SHP2 inhibitor reversed the deleterious effects 
of SLE-associated organ damage, confirming the marked impact 
that increased activity of this enzyme has on SLE etiology. Taken 
ure 8D), as compared with normal patient samples (Figure 8, C 
and D). Conversely, T cells derived from lupus patients treated 
with the SHP2 inhibitor showed reduced clonal expansion (Fig-
ure 8C) and significantly decreased T cell proliferation (Figure 
8D). No differences in viability were observed between vehicle 
and SLE inhibitor–treated cells either in the absence or pres-
ence of inhibitor (Figure 8E), suggesting that SHP2 functions to 
specifically target abnormal T cell proliferation in SLE. No aber-
rant effects were observed in normal patient cells in response 
to inhibitor treatment, suggesting minimal off-target effects in 
human cells (Figure 8C).
Concomitant to the cytokine levels observed in patient serum, 
cultured T cells isolated from SLE patients also showed higher lev-
els of IL-17A/F (Figure 8F) and IFN-γ (Figure 8G) in response to T 
cell activation, as compared with normal patients. The expression of 
Figure 5. SHP2 activity specifically modulates DN T 
cell proliferation to promote aberrant ERK/MAPK, but 
not AKT/mTOR, signaling in this immune cell subset. 
DN T cells isolated from lymph nodes of 18-week-old 
MRL/lpr mice were cultured (3 × 106 cells/well) in 6-well 
plates for 48 hours in the presence of vehicle (DMSO) 
or 11a-1 (10 μg/ml) as well as T cell–activating antibod-
ies anti-CD3 and anti-CD28. Cells were then harvested, 
lysed, and immunoblotted with (A) anti–phospho-AKT 
and anti–phospho-S6RP and (B) anti-phospho-ERK, as 
indicated, followed by anti-AKT, anti-S6RP, anti-SHP2, 
anti-GAPDH, and anti-ERK, respectively, to control for 
loading and protein expression levels. Quantification of 
Western blots from n = 3 independent experiments rep-
resents the mean ± SEM. DN T cells isolated from lymph 
nodes of 18-week-old MRL/lpr mice were cultured (1 × 
105 cells/well) in 96-well plates for 48 hours with either 
vehicle (DMSO) or 11a-1 (10 μg/ml) and in the presence 
or absence of T cell–activating antibodies anti-CD3 and 
anti-CD28 and were assessed for (C) proliferation or (D) 
viability. n = 3 independent experiments. *P < 0.01; #P < 
0.05, 1-way or 2-way ANOVA with Holm-Sidak post-test 
when ANOVA was significant.
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documented; use of a different SHP2 inhibitor (NSC-87877) 
in response to experimental autoimmune encephalomyelitis 
(EAE), an induced autoimmune response, showed resistance 
to the induction of the disease (65). Importantly, T cell–condi-
tional SHP2-deficient mice treated with this drug are no longer 
resistant to EAE, suggesting that inhibition of SHP2 directly con-
tributes to the amelioration of the autoimmune response (65).
Because of its critical role in inflammation, we hypothesized 
that SHP2 could be an integral mediator of SLE pathogenesis. 
Indeed, SHP2 has an already established role as an important reg-
ulator of inhibitory receptor tyrosine kinase signaling in immune 
cells. Specifically, SHP2 is recruited to the cytoplasmic tail of cyto-
toxic T lymphocyte–associated antigen 4 (CTLA-4), programmed 
death-1 (PD-1), B and T lymphocyte attenuator (BTLA), killer cell 
Ig-like receptors (KIRs), and CD31 (PECAM-1) in lymphocytes 
(66–68), likely to mediate dephosphorylation and inactivation 
of these immunoregulatory receptors. Importantly, the effects of 
receptor inactivation can be profound. CTLA-4–deficient mice 
develop severe systemic lymphoproliferative disease and die 
together, our data provide compelling evidence to suggest that 
targeted inhibition of SHP2 activity may be a potent, novel, and 
specific therapy for treatment of patients with SLE.
SHP2 is a ubiquitously expressed protein tyrosine phospha-
tase that modulates nearly all cytokine, integrin, and tyrosine 
receptor signaling pathways. It also appears to have a causal 
genetic link to SLE and other autoimmune-like disorders; 
indeed, more than 50 patients with NS, an autosomal dominant 
disorder principally caused by GOF SHP2 mutations, have been 
subsequently diagnosed with SLE (30–35). Additionally, NS 
mice (SHP2D61G/+) develop splenomegaly, have increased neutro-
phils and leukocytes, and develop an autoimmune-like disease 
(26). Mechanistically, SHP2 is required for T cell development 
and function, including in differentiation, proliferation, and 
migration of these cells (64, 65). Specifically, Lck-Cre–mediated 
deletion of SHP2 in the thymus results in a significant block in 
thymocyte proliferation and differentiation, implicating SHP2 
as a positive regulator of T cell development and function (64). 
Specific involvement for SHP2 in these processes has also been 
Figure 6. SHP2 activity mediates 
production of a specific subset 
of cytokines, IFN-γ, and IL-17A/F 
heterodimers in SLE. Serum from 
18-week-old WT, MpJ, and MRL/lpr 
female mice treated for 6 weeks with 
vehicle or 11a-1 (7.5 mg/kg/d) was 
collected and assessed for levels of 
(A) IL-17A/F or (B) IFN-γ. n = 3–8 mice/
group. DN T cells were isolated from 
MRL/lpr mouse lymph nodes and 
cultured for 120 hours in the presence 
or absence of anti-CD3 and anti-CD28 
antibodies and with either vehicle or 
11a-1. These were assessed for levels 
of (C) IL-17A/F and (D) IFN-γ. n = 3 
independent experiments. Pearson 
correlation analysis showing relation-
ship of kidney dysfunction relative to 
the expression of serum cytokines (E) 
IL-17A/F and (F) IFN-γ from WT, MpJ, 
and MRL/lpr mice, treated with either 
vehicle or 11a-1 for 6 weeks. n = 30. *P 
< 0.01; #P < 0.05, 2-way ANOVA with 
Holm-Sidak post-test when ANOVA 
was significant.
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autoreactivity and autoimmunity (73). Similarly, T cells isolated 
from patients with lupus or treated with the lupus-inducing drug 
hydralazine show that DNA methylation is inhibited and DNMT1 
expression is decreased (43, 73). Our data further support these 
findings and suggest that the regulation of ERK may be modulated 
either directly or indirectly through modulation of the epigenetic 
effects of gene expression by SHP2 (43, 44). Indeed, since ERK/
MAPK activity appears to be tissue or cell specific (26), further 
investigation is required to determine the precise mechanism or 
mechanisms by which SHP2 modulates this pathway in SLE.
Unlike ERK/MAPK activity, PI3K/AKT/mTOR activity is 
increased in SLE-prone MRL/lpr mice as well as in human lupus 
patients (41, 75). PI3K expression exists broadly in immune cells, 
including T cells, B cells, monocytes, macrophages, neutrophils, 
and dendritic cells. As such, PI3K inhibitors or deletion of PI3K 
reduces the chemotactic response of these cell types in both in 
vitro and in vivo migration assays (76). Inhibition of PI3K/AKT 
signaling also ameliorates lupus pathogenicity, as demonstrated 
by a reduction in proteinuria and improvement in the histological 
assessment of the kidney (77). However, inhibition principally tar-
gets B cells and CD4+ memory T cells, leading to decreased pro-
duction of TNF-α and IL-6 and reduced B cell expansion and pro-
duction of autoantibodies (38, 41, 77). In contrast, while our data 
within 3 to 4 weeks after birth (69, 70). PD-1–deficient mice on a 
C57BL/6 background develop late-onset progressive arthritis and 
lupus-like glomerulonephritis (71), and mice on a BALB/c back-
ground develop autoimmune cardiomyopathy (72). Therefore, 
SHP2-mediated inactivation of immunoregulatory receptors may 
contribute to the development of the autoimmune-like pheno-
types described above.
Differential pathways modulate activation of specific immune 
subsets, the aberrant regulation of which may promote concor-
dant SLE-associated organ damage and disease. However, the cel-
lular and mechanistic complexities of these effects in SLE remain 
unclear. In this regard, involvement of ERK/MAPK and PI3K/
AKT/mTOR signaling has been implicated in SLE. Specifically, 
ERK activity is decreased in lupus, and this defective signaling 
causes abnormal T cell epigenetic homeostasis, DNA methylation, 
loss of self tolerance, abnormal cytokine production, acquisition 
of cytotoxic responses, and ultimately, development of autoim-
munity (45, 46). Indeed, T cells treated with ERK/MAPK pathway 
inhibitors become autoreactive in vitro and induce autoimmunity 
in vivo (43, 73, 74). Decreased ERK signaling in T cells alone also 
causes a lupus-like phenotype in mice, reducing DNA methyltrans-
ferase 1 (DNMT1) expression, inducing DNA hypomethylation 
and overexpression of methylation-sensitive genes and leading to 
Figure 7. SHP2 activity is not 
involved in autoantibody 
production. (A) Serum IgG 
and (B) anti-dsDNA IgG were 
measured in 18-week-old WT, 
MpJ, and MRL/lpr female 
mice treated for 6 weeks with 
vehicle or 11a-1 (7.5 mg/kg/d). 
n = 7–8 mice/group. Repre-
sentative flow cytometry and 
corresponding quantification 
of (C) extrafollicular T helper 
cells (Tefh) (TCRβ+CD4+PSGL-1–
CD62L–) and (D) plasmoblasts 
(TCRβ–CD44hiB220+CD138+) 
and plasma cells (TCRβ–
CD44hiB220–CD138+) isolated 
from spleens of 18-week-old 
WT, MpJ, and MRL/lpr female 
mice treated for 6 weeks with 
vehicle or 11a-1 (7.5 mg/kg/d). 
n = 3–5 mice/group. *P < 0.01; 
#P < 0.05, 2-way ANOVA with 
Holm-Sidak post-test when 
ANOVA was significant.
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over, SHP2 activity does not significantly affect serological neu-
trophil, monocyte, or eosinophil populations and does not reduce 
elevated circulating levels of IL-6, TNF-α, or IL-17A/A cytokines, 
suggesting functional specificity of SHP2 for ERK/MAPK, not 
PI3K/AKT/mTOR, signaling in SLE.
indicate that SHP2 inhibition can similarly improve proteinuria 
and kidney function, we believe it is through a different mecha-
nism; here, we show a decrease in proliferation of T cells, not B 
cells, an increase in ERK/MAPK activity, and a decrease in pro-
duction of IFN-γ and IL-17A/F cytokines in MRL/lpr mice. More-
Figure 8. SHP2 also modulates 
proliferation of T cells and 
expression of IFN-γ and IL-17A/F 
in human lupus. Serum levels 
of (A) IL-17A/F and (B) IFN-γ 
were measured from either 
normal or lupus patients with 
SLEDAI scores higher than 7. n 
= 24–25/group. (C) Representa-
tive images of cultured normal 
or lupus patient T cells, isolated 
from PBMCs, following 48 hours 
of culture in the presence of 
vehicle (DMSO) or 11a-1 (10 μg/
ml) and in the absence or pres-
ence of activating antibodies 
anti-CD3 and anti-CD28. Scale 
bar: 500 μm. T cells isolated 
from normal or lupus patients 
were assessed for (D) prolif-
eration and (E) viability (n = 3 
independent experiments) after 
48 hours of culture. In addition, 
T cells isolated from normal or 
lups patients were measured for 
levels of (F) IL-17A/F or (G) IFN-γ 
following 120 hours of culture. n 
= 12–13/ group. *P < 0.05, 1-way 
or 2-way ANOVA with Holm-
Sidak post-test when ANOVA 
was significant.
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A or suberoylanilide hydroxamic acid also improve lupus patho-
genicity (83). Here, inhibition of SHP2 activity blocks DN T cell 
proliferation, leading to decreased IFN-γ and IL-17AF levels and 
to increased ERK activity, ultimately normalizing SLE-associated 
pathogenicity in target tissues. As such, these data suggest SHP2 
activity is integrally involved in SLE and that its normalization may 
be a potent and targeted therapy for treatment of patients with SLE.
Methods
Mice. Mice utilized herein were maintained in a specific pathogen–
free (SPF) animal facility at BIDMC. Briefly, female MRL/MpJ-fas lpr 
(MRL/lpr), MRL/MpJ, and C57BL/6J mice were purchased from the 
Jackson Laboratory. For experimental controls, we utilized female 
C57BL/6 WT mice as well as the lupus background strain (MRL/
MpJ) mice, which do not have the recessive lpr gene mutation that the 
MRL/lpr mice have, but that still develop a late-onset, mild arthri-
tis and glomerulonephritis (38). For experiments, mice within each 
group were subjected to i.p. injections of either vehicle (DMSO) or 
11a-1, a potent, reversible, and specific SHP2 inhibitor (39), at a dos-
age of 7.5 mg/kg/d for a period of 6 weeks, starting at 12 weeks to 18 
weeks of age. Body weight was measured daily, and treatment con-
centrations and volumes were adjusted accordingly. At the end of 
the treatment period, mice were sacrificed with CO2 exsanguination 
and SLE-targeted organs were removed. For each mouse, spleen and 
kidney weight were calculated. In addition, total animal body weight 
and tibia length were measured. Peripheral blood/serum was also col-
lected for cell counts and cytokine assays, described below.
Human PBMC isolation. Deidentified human PBMCs were isolated 
from both normal and SLE patients, and SLE patients were diagnosed 
according to the American College of Rheumatology classification cri-
teria and with an SLE Disease Activity Index (SLEDAI) greater than or 
equal to 7. Healthy sex- and age-matched control cells were also used 
for experiments herein. Briefly, peripheral venous blood was collected 
in heparin-lithium tubes and PBMCs were prepared with Ficoll-Paque 
centrifugation, as previously described (84).
Immune complex PTP assays. PTP assays were conducted as pre-
viously described (85) using para-nitrophenyl phosphate (pNPP) 
(Sigma-Aldrich) as substrate. Briefly, WT C57BL/6, MRL/MpJ, or 
MRL/lpr mouse spleens were homogenized and lysed in RIPA buffer 
(but without sodium orthovanadate), and SHP2, SHP1, and PTPN22 
were immunoprecipitated by using anti-SHP2, anti-SHP1, and anti-
PTPN22 antibodies (Santa Cruz Biotechnology Inc.) coupled to pro-
tein A–Sepharose. The SHP2, SHP1, and PTPN22 immune complexes 
were washed 6 times in RIPA buffer without sodium orthovanadate 
and once in assay buffer (30 mM HEPES, pH 7.4, 120 mM NaCl with-
out pNPP). For each sample, PTP assays were performed in triplicate 
at 37°C in 50 μl of assay buffer (30 mM HEPES, pH 7.4, 120 mM NaCl, 5 
mM dithiothreitol, 10 mM pNPP) containing 50 μl of the SHP2 beads. 
Reactions were terminated with 0.2 N NaOH, and phosphate release 
was determined by measuring A410. Following the assays, immune 
complexes were recovered by centrifugation, boiled in 2× SDS-PAGE 
sample buffer, resolved by SDS-PAGE, and immunoblotted with anti-
SHP2, anti–SHP1, and anti-PTPN22 antibodies, respectively (Santa 
Cruz Biotechnology Inc.) to ensure that equal amounts of SHP2, SHP1, 
and PTPN22 had been tested for phosphatase activity.
Assay for reversibility of the SHP2 inhibitor. SHP2 immunocom-
plexes were washed 6× in RIPA buffer and then, in the presence of 
IFN-γ is required for lupus development, inducing local 
immune and inflammatory signaling processes (78). Moreover, 
while the role for IL-17A/A has been well studied, the function 
of the heterodimer IL-17A/F in SLE remains elusive, though its 
expression has been documented in inflammation (79). Here, 
the differential effect of SHP2 inhibition on IL-17A/F but not 
IL-17A/A homodimer is interesting, particularly since IL-17A/F 
heterodimers signal through the same receptors as IL-17A or IL-17F 
homodimers and induce similar biological responses. Interesting-
ly, recent work in RA has identified specific regulation of the differ-
ent isoforms of IL-17 in human pathogenesis. While the plasma lev-
els of IL-17A, IL-17A/F, and IL-17F were all significantly increased 
in RA, the differences were largest in IL-17F, and only this isoform 
was decreased following methotrexate therapy (80). Taken togeth-
er, these data suggest that regulation of autoimmune diseases may 
not only be dependent on a specific subset of cytokines, but also on 
the expression of specific isoforms of these cytokines as well. We 
are currently investigating the potential contribution of cytokines 
and their isoforms downstream of SHP2 in our laboratory.
Besides affecting cell proliferation, SHP2 is also involved in 
cell migration. As such, inhibition of SHP2 may prevent activated 
T cells from migrating to target organs. This was recently suggest-
ed in the study utilizing the NSC-87877 SHP2 inhibitor, where the 
preventative effects of the drug in EAE were mediated through its 
ability to block migration of T cells into the central nervous system 
(65). Therefore, 11a-1 treatment may function similarly, at least in 
part, and prevent the migration of T cells and inflammatory cells 
into SLE-targeted organs such as the spleen and kidney.
Regrettably, inhibition of SHP2 does not cure SLE; it did not 
decrease production of anti-dsDNA or anti-IgG, despite the pro-
found observed amelioration in overall pathogenicity of the dis-
ease in tissues. Indeed, our data suggest that targeting of down-
stream autoreactive T cells alone may be sufficient to suppress 
SLE-associated organ damage. However, we cannot exclude the 
possibility that subpopulations of B cells are also required, at least 
in part, for this process. Provocatively, these data also suggest that 
autoantibody production may be necessary, but insufficient, in 
mediating the organ damage in SLE, data well in line with accu-
mulating evidence that suggests the same. For example, treatment 
of MRL/lpr mice with IL-2 significantly improved lupus patho-
genicity without altering serum autoantibody levels or immuno-
complex deposits in the kidney (5). Moreover, although there was 
a significant decrease in autoantibody isotypes in ICOS-deficient 
MRL/lpr mice, the renal pathology, as demonstrated by the degree 
of glomerulonephritis and interstitial inflammation, was compa-
rable (81), demonstrating that autoantibody production and tissue 
inflammation may not be concomitantly correlated.
There is no question that new drug development for the treat-
ment of lupus is needed. The current therapeutic regimen is limit-
ed, and SLE is a complicated, multifaceted disease that may require 
targeting of multiple downstream effectors. Perhaps combinatorial 
therapies that include B and T cell inhibitors or SHP2 and PI3K/
AKT inhibitors would help elicit a more positive response. Addi-
tional options may include other downstream targets. For instance, 
animal studies that inhibit cytokine production of IFN-γ show some 
improvement in lupus (82). In addition, reverse epigenetic modifi-
cations by the histone deacetylase (HDAC) inhibitor trichostatin 
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or 11a-1–treated mice were obtained by passing the organs through a 
nylon mesh. Briefly, kidneys were cut into small pieces and homog-
enized on a 70-μm nylon mesh in 5 ml of HBSS buffer. All of the 
homogenized tissues and cells were transferred to new 50-ml tubes 
and digested with collagenase type 4 (100 μg/ml) (Worthington Bio-
chemical Corp.) in HBSS for 30 minutes to 2 hours (37°C) on a rotat-
ing shaker. After digestion, the cells were centrifuged at 780 g for 10 
minutes, and the kidney cell isolates were generated; these included 
infiltrated immune cell subsets.
Spleens were cut into 2 to 3 pieces each and homogenized on 
a 70-μm nylon mesh in 5 ml of HBSS buffer. The cells were filtered 
through a 70-μm nylon mesh to a new 50-ml tube and centrifuged at 
780 g for 5 minutes at room temperature. The pellets were dissolved 
in 1 to 2 ml of rbc lysis buffer (Sigma-Aldrich R7757) for 2 to 5 minutes 
to lyse the rbc. 30 ml of 1× HBSS buffer was added, and the homog-
enate was centrifuged at 780 g for 10 minutes. The pellet, containing 
immune cell subsets and remaining tissue aggregates, was further dis-
solved in 5 ml of HBSS and additionally filtered through a new 70-μm 
nylon mesh to remove these aggregates. Finally the remaining cell 
suspension was centrifuged at 780 g at 4°C for 5 minutes to collect the 
splenocytes, which included the immune cell subsets.
All the isolated cell pellets were dissolved in 1 ml of 0.5% FBS/
PBS buffer in preparation for either cell counting or flow cytometry, 
as described below.
Flow cytometry. To identify immune cell subsets, isolated cells 
from tissues or whole blood were immunostained with mouse anti-
bodies targeted against CD3ε (145-2C11, BioLegend), CD4 (GK1.5, 
BioLegend), CD8 (53–6.7, eBioscience), CD45 (30-F11, eBiosci-
ence), CD19 (6125, BioLegend), CD11b (M1170, BioLegend), TCRβ 
(H57-597, BioLegend), CD44 (IM7, BioLegend), B220 (RA3-6B2, 
BD Biosciences — Pharmingen), CD138 (281-2, BioLegend), CD38 
(CD28.2, BioLegend), Ly6G (RB6.8C5, eBioscience), PSGL-1 (2PH1, 
BD), CD62L (DREG-56, BioLegend), or CD25 (PC61, BioLegend) for 
30 minutes at 4°C. Samples were acquired on a LSR II flow cytometer 
(BD Biosciences), and the percentage of each subpopulation of cells (B 
cells, T cells, monocytes, macrophages, and neutrophils) was assessed 
by FlowJo (version 7.2.2, Tree Star). Total cell numbers were counted 
using a hemocytometer. Absolute cell numbers for each subpopulation 
were calculated based on the percentage of each population.
Purification and culture of mouse and human T cells. Whole tissue cell 
cultures prepared from mouse spleen and axillary lymph nodes were 
generated as described above. From within this total cell preparation, 
total T cells from spleen and the DN T cells from axillary lymph nodes 
were further purified through negative selection using a pan T cell isola-
tion kit from Miltenyi Biotec. In brief, 10 μl of pan T cell biotin-antibody 
cocktail, which includes monoclonal antibodies against CD11b, Cd11c, 
CD19, CD45R (B220), CD49b, CD105, anti–MHC class II, and ter-19, 
was added per 1 × 107 total cells, incubated on ice for 30 minutes, and 
then mixed with 30 μl of D-PBS/0.5% FBS (pH 7.2) per 1 × 107 cells. 
Next, 20 μl of anti-biotin beads were added per 1 × 107 cells and the reac-
tion was kept on ice for another 30 minutes. After centrifuging at 200 g 
for 5 minutes at 4°C, the pellet was resuspended in 2 ml of T cell isolation 
buffer (D-PBS, pH 7.2, 0.5% FBS,and 2 mM EDTA) and the T cells were 
purified through a magnetic sorting column (MACS).
Human T cells were purified from frozen PBMCs isolated from SLE 
or normal donor patients. Briefly, frozen PBMCs were thawed in a 37°C 
water bath for 1 to 2 minutes and then gently added to prewarmed RPMI 
500 μl RIPA buffer, were either treated with 11a-1 (10 μg/ml) or vehi-
cle (DMSO). Complexes were incubated for 5 hours at 4°C and then 
washed in RIPA buffer for the indicated times (0×, 5×, 15×, or 30×). 
A last wash in assay buffer without DTT and pNPP was conducted 
before performing the PTP assay (as described in Immune complex PTP 
assays). For the reaction controls, following the 11a-1 or DMSO incuba-
tion, SHP2 immunocomplexes were immediately washed with assay 
buffer without DTT and pNPP and then subjected to the PTP assay.
Biochemical analyses. Spleens isolated from either vehicle (DMSO) 
or 11a-1–treated WT C57BL/6, MRL/MpJ, or MRL/lpr female mice 
were dissected, perfused in PBS, and immediately frozen in liquid N2. 
Whole-tissue lysates were prepared by homogenizing the tissue in RIPA 
buffer (25 mmol/l Tris-HCl, pH 7.4, 150 mmol/l NaCl, 0.1% SDS, 1% 
NP-40, 0.5% sodium deoxycholate, 5 mmol/l EDTA, 1 mmol/l NaF, 
1 mmol/l sodium orthovanadate, and a protease cocktail) at 4°C, fol-
lowed by clarification at 14,000 g. Proteins were resolved by SDS-PAGE 
and transferred to PVDF membranes. Immunoblots were performed 
on whole lysates, following the manufacturer’s directions, with anti-
AKT (sc-8312), anti-SHP2 (sc-280), anti–phospho-AKT (4060S), anti–
phospho-ERK1/2 (9101L), anti-ERK1/2 (9102L), anti–phospho-p70S6K 
(9234S), anti-p70S6K (9292L), anti–phospho-S6RP (2211S), and anti-
S6RP (2217S) antibodies (Cell Signaling Technology); and anti-GAPDH 
(MAB374) (Millipore). Bands were visualized with enhanced chemilu-
minescence and quantified by densitometry (ImageJ; NIH).
Urinalysis. To determine kidney function, urine was collected 
before mice were sacrificed. Albumin and creatinine in the urine were 
measured using colorimetric assays according to the manufacturer’s 
instructions (Albuwell M; the creatinine companion, Exocell) by 
ELISA, as described below. Kidney function was calculated as ratio of 
albumin to creatinine levels.
Histology. Harvested organs for histology were flushed with PBS, 
perfusion fixed in Bouin’s reagent, and paraffin embedded. Sections 
(5 μm) were stained with H&E, periodic acid–Schiff stain (PAS), or 
Masson’s trichrome at the Harvard Medical School Rodent Histopa-
thology Core and scored using an unbiased and blinded approach by 
Roderick Bronson. Scores were based on a scale of 0–4, as follows: 4, 
most severe, based on appearance of crushed glomeruli and thickness 
of crescents; 3, severe; 2, moderate; 1, mild; 0, appearing normal. We 
took an average severity based upon evaluation of multiple glomeruli 
per kidney. Images of the tissue sections were obtained using a Key-
ence BZ-9000 microscope.
Longevity study. Female MRL/lpr mice survival/longevity was 
assessed by Kaplan-Meier curve analysis. Mice were either i.p. 
injected with vehicle (DMSO) or 11a-1 (7.5 mg/kg/d) beginning at 
12 weeks of age to assess tolerance of the inhibitor and longevity/
survival. The study was terminated when the last vehicle-treated 
MRL/lpr mouse died, at 26 weeks.
Blood cell counts. 50 μl of peripheral blood was collected from mice 
upon sacrifice and mixed with 5 mM EDTA anticoagulant to be used 
for blood cell counts (Hemavet 850FS), to determine numbers of wbc 
(neutrophil, lymphocytes, monocytes, eosinophil, and basophil), rbc, 
and platelets. In addition, peripheral blood isolated from MRL/lpr 
mice either treated with vehicle (DMSO) or 11a-1 was used to count the 
percentage of leukocyte subsets, including B cells, T cells, and T cell 
subsets (CD4+, CD8+, and DN T cells), by flow cytometry (see below).
Total cell isolation from SLE-prone tissues (kidney, spleen). Single-
cell suspensions from excised kidneys and spleens from either vehicle 
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used and loaded onto a precoated 96-well plate in duplicate for 1 
hour at room temperature. As per the protocol instructions, enzyme-
antibody conjugate, TMB substrate, and stopping buffer were added 
sequentially. The OD of the wells was determined using a microplate 
reader set at a wavelength of 450 nm.
Albumin and creatinine levels. For the albumin assay, collected 
mouse urine was diluted at 1:5200× and 50 μl was loaded onto an 
precoated albumin 96-well plate, followed by primary incubation, sec-
ondary incubation, and colorimetric determination. For the creatinine 
assay, the urine was diluted 20× and loaded onto a 96-well plate, and 
picrate working solution and acid reagent were added sequentially 
according to protocol. Absorbance was assayed using a plate reader set 
at a wavelength of 495 nm.
Statistics. All data are expressed as mean ± SEM. Statistical sig-
nificance was determined using 2-tailed Student’s t test and 1-way 
ANOVA or 2-way repeated-measures ANOVA, as appropriate. If ANO-
VA was significant, individual differences were evaluated using the 
Holm-Sidak post-test. For all studies, values of P < 0.05 were consid-
ered statistically significant.
Study approval. All procedures were performed in accordance with 
the NIH Guide for the Care and Use of Laboratory Animals (National 
Academies Press. 2011.) and experimental protocols were approved 
by the IACUC at BIDMC (protocol number 070-2014). In addition, 
deidentified human PBMCs were obtained for this study from the 
Division of Rheumatology at BIDMC in accordance and with approval 
by the IRB at BIDMC. SLE patients were recruited by the Division of 
Rheumatology at BIDMC under IRB protocol 2006-P-0298.
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1640 medium with 10% FBS (total 10 ml). After incubating at 37°C for 1 
hour, the cells were centrifuged at 250 g for 5 minutes at room tempera-
ture. The cell pellet was washed with 5 ml of prewarmed RPMI 1640 
medium with 10% FBS 3 times, followed by a final D-PBS (no calcium, 
no magnesium buffer) wash. Human T cells were then purified by a Pan 
T Cell Isolation Kit (human) from Miltenyi Biotec, as described above.
The purity of isolated T cells routinely exceeded 94%. After puri-
fication, T cells were resuspended in RPMI 1640 medium with 10% 
FBS, and 1 × 105 cells/well in 100 μl total volume was loaded onto a 
96-well plate, either left uncoated or precoated with anti-CD3 anti-
body (1 μg/ml) (OKT3; BioLegend). All cells loaded onto wells precoat-
ed with anti-CD3 antibody were also mixed with anti-CD28 antibody 
(0.5 μg/ml) (CD28.2; BioLegend) to help potentiate the T cell signal-
ing response. Plated cells were then cultured for 48 or 120 hours in the 
presence of either vehicle (DMSO) or 11a-1 (10 μg/ml). Following incu-
bation, 15 μl of medium was collected for the various cytokine activity 
analyses, as described above.
T cell proliferation and viability assays. For cell viability, an MTT 
(Thiazolyl Blue Tetrazolium Bromide, M2128, Sigma-Aldrich) assay was 
employed. Briefly, 10 μl of the MTT-labeling reagent (final concentra-
tion 0.5 mg/ml) was loaded into each cell culture well (96-well plate) 
and then incubated for 4 hours in a humidified chamber. Following 
incubation, 100 μl of solubilization solution (0.04 N in absolute isopro-
panol) was added to each well, resuspended, and then incubated at 37°C 
for an additional hour. Spectrophotometric absorbance of the samples 
was assessed using a microplate reader at a wavelength of 595 nm. T cell 
numbers and proliferation were assessed by cell count using a hemocy-
tometer. In brief, 1 × 105 cells were plated in each well and cultured for 
48 hours. 10 μl of cell suspension was then removed and mixed together 
with 10 μl of Trypan blue solution (0.4%, T8154, Sigma-Aldrich). After 
mixing, 10 μl of the mixture was loaded onto the hemocytometer and 
the total average number of cells/well was calculated.
ELISA. ELISA assays were used to detect for the presence of vari-
ous cytokines in mouse serum isolated from vehicle or drug-treated 
animals or from medium supernatant isolated from tissue cell cul-
tures as described above. ELISA was also used to detect total IgG and 
dsDNA IgG from mouse serum and for detection of albumin and cre-
atinine from urine. ELISA detection kits for mouse cytokines IL-6 and 
TNF-α were purchased from eBioscience, mouse cytokines IL-17A, IL-
17A/F, IFN-γ, and human IFN-γ were purchased from BioLegend, kits 
for the albumin and creatinine were purchased from Exocell, and kits 
for the serum IgG and anti-dsDNA IgG were purchased from Alpha 
Diagnostic International Inc. ELISAs were all performed according to 
the manufacturer’s instructions.
Cytokine analyses. In brief, capture antibodies for each cytokine 
were precoated on 96-well plates overnight at 4°C, then 100 μl of 5× 
diluted serum or 300× diluted supernatant medium was loaded on 
the precoated wells in duplicate and left overnight at 4°C (with the 
exception of the human IFN-γ assay isolated from supernatant medi-
um, where the dilution used was 1:30). As per the protocol instruc-
tions, enzyme-antibody conjugate, TMB substrate, and stopping buf-
fer were added sequentially. The colorimetric analysis, as measured 
by OD within each well, was determined using a microplate reader set 
at a wavelength of 450 nm. The cytokine concentrations were calcu-
lated and measured against a standard curve for each cytokine.
Serum IgG and anti-dsDNA IgG. 100 μl of 1:50000× diluted serum 
for IgG and 100 μl of 1:20000× diluted serum for dsDNA IgG were 
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